Details of the Drug
General Information of Drug (ID: DMAEN9Y)
Drug Name |
Adamantan-1-yl-pyrrolidin-1-yl-methanone
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Adamantan-1-yl-pyrrolidin-1-yl-methanone; CHEMBL392866; 1-adamantyl(1-pyrrolidinyl)methanone; 22508-51-6; (3r,5r,7r)-adamantan-1-yl(pyrrolidin-1-yl)methanone; 1-adamantyl(pyrrolidin-1-yl)methanone; AC1MCDV9; CBMicro_007397; Cambridge id 5142982; Oprea1_111627; Oprea1_295021; MLS000526196; adamantanyl pyrrolidinyl ketone; SCHEMBL3456185; MolPort-001-930-821; HMS2477C05; HMS1608M03; ZINC4031845; SMSF0003738; STK091400; BDBM50207788; 1-(adamantane-1-carbonyl)pyrrolidine; AKOS000612243; CCG-246226; CB09819; MCULE-7009966643
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 233.35 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||